B9305

BW 245C

≥98% (HPLC), solid

• Synonym(e): 3-(3-Cyclohexyl-3-hydroxypropyl)-2,5-dioxo-(R*,S*)-(±)-4-imidazolineheptanioc acid
• Empirische Formel (Hill-System): C₁₉H₃₂N₂O₅
• CAS-Nummer: 72814-32-5
• Molekulargewicht: 368.47
• UNSPSC-Code: 12352200
• PubChem Substanz-ID: 24278046

Eigenschaften

• Assay: ≥98% (HPLC)
• Form: solid
• Farbe: off-white
• Löslichkeit: DMSO: soluble 10 mg/mL
• Ersteller: GlaxoSmithKline
• Lagertemp.: −20°C
• SMILES String: O[C@H](CCN1[C@@H](CCCCCCC(O)=O)C(=O)NC1=O)C2CCCCC2
• InChI: 1S/C19H32N2O5/c22-16(14-8-4-3-5-9-14)12-13-21-15(18(25)20-19(21)26)10-6-1-2-7-11-17(23)24/h14-16,22H,1-13H2,(H,23,24)(H,20,25,26)/t15-,16+/m0/s1
• InChIKey: ZIDQIOZJEJFMOH-JKSUJKDBSA-N
• Angaben zum Gen: human ... PTGDR(5729)

Beschreibung

Biochem./physiol. Wirkung

BW 245C was investigated for the affinities potencies, and intrinsic activities in comparison with other natural and synthetic prostanoids using endogenous receptors. The rank order of compound affinities at the DP receptor was SQ27986 (K(i) = 10 +/- 2 nM) > RS93520 = ZK110841 = BW245C (K(i) = 23-26 nM) > ZK118182 (K(i) = 50 +/- 9 nM) > PGD(2) (K(i) = 80 +/- 5 nM). DP receptor agonists produced cAMP in embryonic bovine tracheal fibroblasts with different potencies (EC(50) values in nM): ZK118182 (18 +/- 6), RS93520 (28 +/- 6), SQ27986 (29 +/- 7), ZK110841 (31 +/- 7), BW245C (53 +/- 16), and PGD(2) (98 +/- 10). BW245C was more efficacious and RS93520 was less efficacious.

Leistungsmerkmale und Vorteile

This compound is featured on the Prostanoid Receptors page of the Handbook of Receptor Classification and Signal Transduction. To browse other handbook pages, click here.

This compound was developed by GlaxoSmithKline. To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here.

Sicherheitshinweise

• Lagerklassenschlüssel: 13 - Non Combustible Solids
• WGK: WGK 3
• Flammpunkt (°F): Not applicable
• Flammpunkt (°C): Not applicable
• Persönliche Schutzausrüstung: Eyeshields, Gloves, type N95 (US)